Prospera Financial Services Inc Raises Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Prospera Financial Services Inc lifted its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 12.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 168,885 shares of the biopharmaceutical company’s stock after purchasing an additional 19,315 shares during the quarter. Prospera Financial Services Inc owned about 0.34% of Puma Biotechnology worth $431,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Rice Hall James & Associates LLC grew its stake in Puma Biotechnology by 3.3% during the 2nd quarter. Rice Hall James & Associates LLC now owns 144,792 shares of the biopharmaceutical company’s stock valued at $472,000 after purchasing an additional 4,686 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in Puma Biotechnology by 72.7% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 8,000 shares during the last quarter. Royce & Associates LP boosted its position in Puma Biotechnology by 71.8% in the third quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 8,427 shares during the last quarter. SG Americas Securities LLC acquired a new position in Puma Biotechnology in the 1st quarter worth approximately $57,000. Finally, Squarepoint Ops LLC raised its position in Puma Biotechnology by 17.7% during the 2nd quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 10,757 shares during the last quarter. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Puma Biotechnology Trading Up 3.4 %

Shares of NASDAQ:PBYI opened at $3.00 on Monday. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. Puma Biotechnology, Inc. has a 12-month low of $2.22 and a 12-month high of $7.73. The business has a 50 day moving average of $2.77 and a two-hundred day moving average of $3.16. The company has a market capitalization of $147.27 million, a PE ratio of 6.25 and a beta of 1.09.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.10. The firm had revenue of $80.50 million during the quarter, compared to analysts’ expectations of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same period in the previous year, the business posted $0.12 EPS. As a group, analysts forecast that Puma Biotechnology, Inc. will post 0.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research note on Wednesday, November 20th. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.